Panel data from 1200 US-listed firms shows a positive relationship between share repurchases and market longevity, suggesting important implications for corporate payout strategies.
The 2020 CARES Act brought forth a renewed discussion on share repurchases, reigniting the debate on the net benefits of this payout mechanism. Fueled by theoretical and empirical evidence both in favor of and against share repurchases, we examine how the composition of corporate payouts impacts firms’ market longevity. Leveraging panel data from 1200 US‐listed firms spanning from 2000 to 2020, our study uncovers a positive relationship between a payout composition that prioritizes share repurchases over dividends and market longevity. Our findings suggest that the benefits associated with this payout mechanism outweigh its costs, thereby enhancing firms' resilience in remaining listed in the organized capital markets for extended periods. Furthermore, our results withstand a battery of robustness checks, offering valuable insights for managers, regulators, and the investor community.
No takes yet. Share an insight, caveat, or question.
Chasiotis et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: